280 related articles for article (PubMed ID: 31709671)
1. Dual-Locking Nanoparticles Disrupt the PD-1/PD-L1 Pathway for Efficient Cancer Immunotherapy.
Zhang Z; Wang Q; Liu Q; Zheng Y; Zheng C; Yi K; Zhao Y; Gu Y; Wang Y; Wang C; Zhao X; Shi L; Kang C; Liu Y
Adv Mater; 2019 Dec; 31(51):e1905751. PubMed ID: 31709671
[TBL] [Abstract][Full Text] [Related]
2. Effect of CRISPR/Cas9-Edited PD-1/PD-L1 on Tumor Immunity and Immunotherapy.
Xu Y; Chen C; Guo Y; Hu S; Sun Z
Front Immunol; 2022; 13():848327. PubMed ID: 35300341
[TBL] [Abstract][Full Text] [Related]
3. Programmed cell death ligand 1 disruption by clustered regularly interspaced short palindromic repeats/Cas9-genome editing promotes antitumor immunity and suppresses ovarian cancer progression.
Yahata T; Mizoguchi M; Kimura A; Orimo T; Toujima S; Kuninaka Y; Nosaka M; Ishida Y; Sasaki I; Fukuda-Ohta Y; Hemmi H; Iwahashi N; Noguchi T; Kaisho T; Kondo T; Ino K
Cancer Sci; 2019 Apr; 110(4):1279-1292. PubMed ID: 30702189
[TBL] [Abstract][Full Text] [Related]
4. Dual-Responsive Core-Shell Tecto Dendrimers Enable Efficient Gene Editing of Cancer Cells to Boost Immune Checkpoint Blockade Therapy.
Liu J; Li G; Guo H; Ni C; Gao Y; Cao X; Xia J; Shi X; Guo R
ACS Appl Mater Interfaces; 2023 Mar; 15(10):12809-12821. PubMed ID: 36853989
[TBL] [Abstract][Full Text] [Related]
5. Genome editing of PD-L1 mediated by nucleobase-modified polyamidoamine for cancer immunotherapy.
Wei S; Shao X; Liu Y; Xiong B; Cui P; Liu Z; Li Q
J Mater Chem B; 2022 Feb; 10(8):1291-1300. PubMed ID: 35141737
[TBL] [Abstract][Full Text] [Related]
6. Remodeling Tumor Immunogenicity with Dual-Activatable Binary CRISPR Nanomedicine for Cancer Immunotherapy.
Xing Y; Yang J; Wang Y; Wang C; Pan Z; Liu FL; Liu Y; Liu Q
ACS Nano; 2023 Mar; 17(6):5713-5726. PubMed ID: 36897187
[TBL] [Abstract][Full Text] [Related]
7. Reshaping Tumor Immune Microenvironment through Acidity-Responsive Nanoparticles Featured with CRISPR/Cas9-Mediated Programmed Death-Ligand 1 Attenuation and Chemotherapeutics-Induced Immunogenic Cell Death.
Tu K; Deng H; Kong L; Wang Y; Yang T; Hu Q; Hu M; Yang C; Zhang Z
ACS Appl Mater Interfaces; 2020 Apr; 12(14):16018-16030. PubMed ID: 32192326
[TBL] [Abstract][Full Text] [Related]
8. Recent progress, perspectives, and issues of engineered PD-L1 regulation nano-system to better cure tumor: A review.
Zhou Z; Wang H; Li J; Jiang X; Li Z; Shen J
Int J Biol Macromol; 2024 Jan; 254(Pt 2):127911. PubMed ID: 37939766
[TBL] [Abstract][Full Text] [Related]
9. Virus-like nanoparticle as a co-delivery system to enhance efficacy of CRISPR/Cas9-based cancer immunotherapy.
Liu Q; Wang C; Zheng Y; Zhao Y; Wang Y; Hao J; Zhao X; Yi K; Shi L; Kang C; Liu Y
Biomaterials; 2020 Nov; 258():120275. PubMed ID: 32798741
[TBL] [Abstract][Full Text] [Related]
10. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
[TBL] [Abstract][Full Text] [Related]
11. A rapid and efficient platform for antiviral crRNA screening using CRISPR-Cas13a-based nucleic acid detection.
Yang L; Zhang Y; Yi W; Dong X; Niu M; Song Y; Han Y; Li H; Sun Y
Front Immunol; 2023; 14():1116230. PubMed ID: 37228594
[TBL] [Abstract][Full Text] [Related]
12. Programmable Unlocking Nano-Matryoshka-CRISPR Precisely Reverses Immunosuppression to Unleash Cascade Amplified Adaptive Immune Response.
Yang J; Li Z; Shen M; Wang Y; Wang L; Li J; Yang W; Li J; Li H; Wang X; Wu Q; Gong C
Adv Sci (Weinh); 2021 Jul; 8(13):2100292. PubMed ID: 34258164
[TBL] [Abstract][Full Text] [Related]
13. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure).
Kim JM; Chen DS
Ann Oncol; 2016 Aug; 27(8):1492-504. PubMed ID: 27207108
[TBL] [Abstract][Full Text] [Related]
14. A programmable hierarchical-responsive nanoCRISPR elicits robust activation of endogenous target to treat cancer.
Liu C; Wang N; Luo R; Li L; Yang W; Wang X; Shen M; Wu Q; Gong C
Theranostics; 2021; 11(20):9833-9846. PubMed ID: 34815789
[TBL] [Abstract][Full Text] [Related]
15. Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer.
Drakes ML; Mehrotra S; Aldulescu M; Potkul RK; Liu Y; Grisoli A; Joyce C; O'Brien TE; Stack MS; Stiff PJ
J Ovarian Res; 2018 May; 11(1):43. PubMed ID: 29843813
[TBL] [Abstract][Full Text] [Related]
16. Generation of Cancer-Specific Cytotoxic PD-1
Lu S; Yang N; He J; Gong W; Lai Z; Xie L; Tao L; Xu C; Wang H; Zhang G; Cao H; Zhou C; Zhong L; Zhao Y
J Biomed Nanotechnol; 2019 Mar; 15(3):593-601. PubMed ID: 31165703
[TBL] [Abstract][Full Text] [Related]
17. Regulating the immunosuppressive tumor microenvironment to enhance breast cancer immunotherapy using pH-responsive hybrid membrane-coated nanoparticles.
Gong C; Yu X; Zhang W; Han L; Wang R; Wang Y; Gao S; Yuan Y
J Nanobiotechnology; 2021 Feb; 19(1):58. PubMed ID: 33632231
[TBL] [Abstract][Full Text] [Related]
18. Stearyl polyethylenimine complexed with plasmids as the core of human serum albumin nanoparticles noncovalently bound to CRISPR/Cas9 plasmids or siRNA for disrupting or silencing PD-L1 expression for immunotherapy.
Cheng WJ; Chen LC; Ho HO; Lin HL; Sheu MT
Int J Nanomedicine; 2018; 13():7079-7094. PubMed ID: 30464460
[TBL] [Abstract][Full Text] [Related]
19. Hierarchical self-uncloaking CRISPR-Cas13a-customized RNA nanococoons for spatial-controlled genome editing and precise cancer therapy.
Fan N; Bian X; Li M; Chen J; Wu H; Peng Q; Bai H; Cheng W; Kong L; Ding S; Li S; Cheng W
Sci Adv; 2022 May; 8(20):eabn7382. PubMed ID: 35584220
[TBL] [Abstract][Full Text] [Related]
20. Universal theranostic CRISPR/Cas13a RNA-editing system for glioma.
Wu Y; Wang Y; Zhou J; Wang J; Zhan Q; Wang Q; Yang E; Jin W; Tong F; Zhao J; Hong B; Liu J; Kang C
Theranostics; 2023; 13(15):5305-5321. PubMed ID: 37908718
[No Abstract] [Full Text] [Related]
[Next] [New Search]
